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Background: Mycobacterium avium subsp. paratuberculosis (MAP) is the cause of Johne’s disease, an enteric
granulomatous disease. Recently, MAP has been associated with different autoimmune diseases such as Crohn’s
disease, type 1 diabetes (T1D) and multiple sclerosis. Transthyretin (TTR) is a plasma transport protein for thyroid
hormone and forms a complex with retinol-binding protein. Reduced TTR plasma levels in MAP infected ovines
have been reported.
TTR exerts also a functional role in the pancreas promoting insulin release and protecting β-cells from death.
Our objective was to identify a protein that could be used as a diagnostic marker of T1D for determining disease
progression and monitoring at-risk patients. We postulate that serological TTR levels would be reduced in T1D MAP
exposed patients. Our hypothesis is based on the observation of cases of T1D patients with decreased TTR levels
beside the reduced TTR plasma levels in ovines with Johne’s disease.
We quantified the plasma protein levels of TTR in 50 people with T1D and 51 age-matched healthy controls (HCs)
by means of enzyme-linked immunosorbent assays (ELISA).
Findings: Our pilot study showed that plasma TTR levels were not significantly lower/higher in T1D Sardinian cases
compared to the HCs.
Conclusion: These preliminary data indicate that plasma TTR may not be a good candidate biomarker for T1D
diagnosis and further studies to elucidate the possible link are needed.
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T1D is a chronic autoimmune disease characterized by
progressive T cell mediated β-cell destruction. The pres-
ence of autoantibodies (aAbs) against islet antigens is a
hallmark for the development of T1D [1]. Islet aAbs titers
against glutamic acid decarboxylase (GAD65), insulinoma
associated protein-2 (IA-2), and zinc transporter 8 (Znt8)
are routinely measure out alone or in combination as bio-
markers for T1D risk assessment. They are as well useful
in the identification and characterization of adult-onset
autoimmune diabetes [2]. Notwithstanding the aforemen-
tioned biomarkers, the existing tests for T1D prediction* Correspondence: sechila@uniss.it
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reproduction in any medium, provided the orare still imperfect and newer biomarkers need to be found.
Transthyretin (TTR) is a 55 kDa homotetramer and it is
the major carrier of serum thyroxine, tri-iodothyronine,
and vitamin A (retinol) through association with retinol-
binding protein [3].
TTR exerts also a functional role in the pancreas pro-
moting insulin release and protecting β-cell from death
[4]. Interestingly a mass spectrometry surface-enhanced
laser desorption ionisation time of flight (SELDI TOF)-
based proteomics study has recently been used to iden-
tify potential ovine paratuberculosis diagnostic markers.
Analysis of the whole serum led to the identification of
TTR as putative biomarker in sheep with MAP exposure
[5]. Moreover another protein-based study using the
isobaric tag for relative and absolute quantitation (iTRAQ)
method showed that TTR is significantly increased in para-
tuberculosis infected cattle compared to controls [6]. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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decreased in human subjects with T1D [7].
We wanted to explore if TTR would be a suitable bio-
marker for T1D risk assessment in Mycobacterium avium
subspecies paratuberculosis (MAP) exposed individuals.
We have previously demonstrated that MAP infection
could be a risk factor for T1D in the Sardinian popula-
tion [8]. To assess TTR eligibility as T1D diagnostic
markers, we investigated whether TTR serum levels
would be reduced in Sardinian T1D patients compared
to HCs. Serum samples of 50 T1D and 51 HCs were
analyzed by MBS Human-TTR ELISA kit.
Methods
Sera
The sera of T1D patients (n = 50; mean age at onset 33.5 ±
7 years), diagnosed according to the American Association
of Diabetes criteria [9] and HCs (n = 51) age-matched with
T1D patients (mean age 36.36 ± 7 years) were obtained
from the University Hospital of Sassari in agreement with
the local ethical committee guidelines. All the samples were
collected from patients and individuals who did not have
any concurrent chronic or autoimmune diseases. All the
collected sera were stored in −20°C until measurements
were carried out. Written informed consent to take part in
the study was obtained from all subjects according to the
guidelines of the Institutional Ethical Committee.
ELISA
ELISA was carried out, as described elsewhere [8] to
detect Abs specific for MAP3865c peptides.
The concentration of TTR in serum samples from
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Figure 1 Acquired TTR ELISA data are displayed by a box plot. The ca
T1D patients.an ELISA kit (MBS, The Netherlands) following the
manufacturer’s instructions.
Statistical evaluation
The statistical significance of the data was determined
by both the Fisher’s exact test and the independent Stu-
dent’s t-test using Graphpad Prism 5.0 software. The p-
value was calculated for each experiment carried out in
triplicate.
Result
Ab positivity against MAP3865c peptides was detected
in 45% of T1D and only in 8.5% of HCs (Fisher’s exact
test; p < 0.0001), showing a statistically significant higher
frequency in T1D.
TTR serum concentrations on 50 T1D and 51 HCs
subjects were assessed performing ELISA according to
the (kit) manufacturer’s instructions. The determined me-
dian concentrations of TTR in the sera from HCs were
285 μg/ml and 207.6 μg/ml for T1D patients. In Figure 1
data are shown in a box plot. The HCs group showed
a mean of 289.5 μg/ml TTR protein and the T1D
group a mean of 217.5 μg/ml (p < 0.0001). When divi-
ding TTR serum levels according to MAP3865cAb posi-
tivity, the MAP3865cAb + T1D patients showed a lower
TTR concentration compared to the HCs (184.2 μg/ml vs
347.6 μg/ml; p < 0.0001) (Table 1). However there was no
correlation between positivity for anti-MAP3865c Abs
and lower/higher TTR serum level, as in both cases data
fit in the physiological range. In fact, according to UniProt
Declaration, the normal fluctuation of TTR in the sera
should range from 100 μg/ml to 400 μg/ml. Unfortunately,
insulin and glucose levels were not available for all the                              T1D  
lculated median concentration is 285 μg/ml in HCs and 207.6 μg/ml in
Table 1 Plasma transthyretin (TTR ) concentration (μg/ml)
determined by ELISA
T1D HCs p values
TOTAL 217.5 ± 69.8 289.5 ± 63 p < 0.0001
MAP3865c Ab + 184.2 ± 59 347.6 ±34 p < 0.0001
MAP3865c Ab - 248.3 ± 64.3 284.5 ± 61.9 p = 0.0216
Values (μg/ml) are MEAN ± SEM.
Levels of TTR protein (mean ± SE) are reported for control subjects (HCs) and
type 1 diabetes (T1D) patients. Furthermore, T1D and HCs mean were as well
calculated dividing for MAP3865cAb + and MAP3865cAb-.
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TTR levels and T1D in a MAP infected population could
not be demonstrated by the use of ELISA even if a trend
towards TTR down-regulation in T1D MAP3865cAb +
patient was identified (184.2 μg/ml vs 347.6 μg/ml
p < 0.0001).
Conclusion
Blood-based biomarkers have an advantage in that they
are suitable for large scale studies with the ease of vene-
puncture and allowing for repeatability in clinical settings.
A previous proteomics study using SELDI-TOF showed
decreased levels of TTR in plasma of MAP exposed sheep
[5]. Conversely an increase in plasma TTR levels was
found in MAP infected cattle [6]. Noteworthy low levels
of vitamin A, correlating with reduced TTR and raised
concentrations of C-reactive protein, have been reported
in patients with tuberculosis [10,11].
Given some studies linking MAP to T1D [8], and the
reported reduction of TTR plasma levels, in T1D
patients compared to HCs [7], we sought to investigate
if MAP infection is associated to TTR down-regulation
in humans T1D subject.
We consider a new approach for diagnosing T1D using
serum from patients with the disease and HCs all from
Sardinian region. In this preliminary study we were
interested to analyze TTR profiles as diagnostic markers
and to infer if TTR distinguished T1D from HCs.
We were not able to find TTR levels below threshold in
T1D and MAP3865cAb + patients.
Our findings, indeed, showed that there is not a reduc-
tion of TTR serological level in Sardinian T1D MAP
exposed individuals, but if we divide the population under
scrutiny according to MAP3865cAb+, we find out that
T1D group display diminished TTR (mean) concentration.
It is as well important to check TTR potential to be a
prognostic marker of T1D, and to accomplish this goal it
is mandatory to set up a follow-up study, to understand if
the lack of correlation could be explained taking into ac-
count the disease stage. Is it the same in recent onset
patients or at 6 months, 1 year or 2 years after the onset?
However, a drawback of this study could the limited
number of subjects. A larger study population and differentpatient cohorts (not Sardinian) as well should be
assessed to fully answer the question if T1D patients and
at risk subjects could be identified on the basis of a signifi-
cantly lower TTR serum concentration.
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